Unicycive Therapeutics Highlights September Investor Engagements

Author: Owen Jenkins Updated: 08-26-2025 07:08 AM

Unicycive Therapeutics Announces September Investor Events

Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a company dedicated to developing innovative therapies for kidney disease, has shared exciting news about its participation in significant investor events this September. Shalabh Gupta, M.D., the Chief Executive Officer, will be at the forefront of these engagements, showcasing the company’s commitment to addressing kidney health challenges.

Upcoming Events Overview

H.C. Wainwright Annual Global Investment Conference

One of the highlights of this month will be the participation at the prestigious H.C. Wainwright 27th Annual Global Investment Conference. Unicycive will engage in a fireside chat scheduled for September 10, where they will connect with investors and share insights into their latest developments.

Truist Securities Virtual Fireside Chat

Adding to the momentum, Unicycive will also feature in a virtual fireside chat hosted by Truist Securities on September 17. This event promises an engaging dialogue focused on the company's strategic initiatives and breakthroughs in kidney disease treatment.

About Unicycive Therapeutics

At the heart of Unicycive is a mission to develop novel treatment options for patients dealing with kidney diseases. The company’s flagship investigational product, oxylanthanum carbonate, is currently receiving evaluation by the U.S. Food and Drug Administration (FDA). This treatment is designed to address hyperphosphatemia, a common complication for patients undergoing dialysis due to chronic kidney disease. Additionally, their second treatment, UNI-494, is being explored for its potential to combat conditions related to acute kidney injury, having already received orphan drug designation for the prevention of Delayed Graft Function in transplant patients.

Engaging with Stakeholders

Unicycive welcomes opportunities for one-on-one meetings during the investor events. Interested parties are encouraged to reach out to schedule a discussion. Engaging with investors directly allows Unicycive to provide an in-depth view of their ongoing research and development efforts, ensuring that they remain aligned with market expectations and healthcare needs.

Contact Information

For inquiries pertaining to investments, stakeholders can reach Kevin Gardner at LifeSci Advisors via email. He is available to facilitate discussions regarding the company’s strategic direction and upcoming milestones. Meanwhile, media inquiries can be directed to Rachel Visi at Real Chemistry, who will be able to provide further insights and information regarding Unicycive’s innovative studies and community impact.

Frequently Asked Questions

What is Unicycive Therapeutics known for?

Unicycive Therapeutics specializes in developing innovative therapies aimed at treating kidney diseases, leveraging advanced medical research.

Who will represent Unicycive at the investor events?

Shalabh Gupta, M.D., the CEO of Unicycive, will be representing the company at the upcoming investor events.

What treatments is Unicycive currently developing?

Unicycive is developing oxylanthanum carbonate and UNI-494, which target chronic kidney disease complications and acute kidney injury, respectively.

How can investors schedule a meeting with Unicycive management?

Investors can schedule a one-on-one meeting by contacting their conference representative during the events.

Where can I learn more about Unicycive Therapeutics?

More information about Unicycive and their therapeutic developments can be found on their official website, where updates on investor relations and product advancements are regularly posted.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.